Changes in Peripapillary Nerve Fiber Layer Thickness after Adjuvant Stereotactic Radiotherapy in Patients with Neovascular Age-Related Macular Degeneration

References

• Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900–01. doi:10.1001/jama.291.15.1900.
   PubMed Web of Science ®Google Scholar
• Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257–93. doi:10.1016/S0039-6257(03)00030-4.
   PubMed Web of Science ®Google Scholar
• Campbell JP, Bressler SB, Bressler NM. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol. 2012;130:794–95. doi:10.1001/archophthalmol.2011.2480.
   PubMedGoogle Scholar
• Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220–26. doi:10.1136/bjophthalmol-2014-305327.
   PubMed Web of Science ®Google Scholar
• Mantel I. Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements. Transl Vis Sci Technol. 2015;4: doi:10.1167/tvst.4.3.6.
   Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON. Ophthalmology. 2013;120:2292–99. doi:10.1016/j.ophtha.2013.03.046.
   PubMed Web of Science ®Google Scholar
• Zinkernagel MS, Schorno P, Ebneter A, Wolf S. Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant. Invest Ophthalmol Vis Sci. 2015;56:1894–900. doi:10.1167/iovs.14-16204.
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Daniel E, Huang J, Ying G-S, Maguire MG, Toth CA, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121:150–61. doi:10.1016/j.ophtha.2013.08.015.
   PubMed Web of Science ®Google Scholar
• Ranjbar M, Brinkmann MP, Tura A, Rudolf M, Miura Y, Grisanti S. Ranibizumab interacts with the VEGF-A/VEGFR-2 signaling pathway in human RPE cells at different levels. Cytokine. 2016;83:210–16. doi:10.1016/j.cyto.2016.04.014.
   PubMed Web of Science ®Google Scholar
• Ranjbar M, Brinkmann MP, Zapf D, Miura Y, Rudolf M, Grisanti S. Fc receptor inhibition reduces susceptibility to oxidative stress in human RPE cells treated with bevacizumab, but not aflibercept. Cell Physiol Biochem. 2016;38:737–47. doi:10.1159/000443030.
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Carmeliet P. VEGF:once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays. 2004;26:943–54. doi:10.1002/bies.20092.
   PubMed Web of Science ®Google Scholar
• Sondell M, Lundborg G, Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci. 1999;19:5731–40.
   PubMed Web of Science ®Google Scholar
• Nishijima K, Ng Y-S, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53–67. doi:10.2353/ajpath.2007.061237.
   PubMed Web of Science ®Google Scholar
• Horsley MB, Mandava N, Maycotte MA, Kahook MY. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. Am J Ophthalmol. 2010;150:558–561.e1. doi:10.1016/j.ajo.2010.04.029.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Shin KC, Chung H, Kim HC. Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2014;55:2403–11. doi:10.1167/iovs.13-13769.
   PubMed Web of Science ®Google Scholar
• Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2012;53:6214–18. doi:10.1167/iovs.12-9875.
   PubMed Web of Science ®Google Scholar
• Kishan AU, Modjtahedi BS, Morse LS, Lee P. Radiation therapy for neovascular age-related macular degeneration. Int J Radiat Oncol Biol Phys. 2013;85:583–97. doi:10.1016/j.ijrobp.2012.07.2352.
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser PK, Gertner M. Stereotactic low-voltage x-ray irradiation for age-related macular degeneration. Br J Ophthalmol. 2011;95:185–88. doi:10.1136/bjo.2009.163907.
   PubMed Web of Science ®Google Scholar
• Jackson TL, Chakravarthy U, Slakter JS, Muldrew A, Shusterman EM, O'Shaughnessy D, Arnoldussen M, Gertner ME, Danielson L, Moshfeghi DM. Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study. Ophthalmology. 2015;122:138–45. doi:10.1016/j.ophtha.2014.07.043.
   PubMed Web of Science ®Google Scholar
• Ranjbar M, Kurz M, Holzhey A, Melchert C, Rades D, Grisanti S. Stereotactic radiotherapy in neovascular age-related macular degeneration: real-life efficacy and morphological evaluation of the outer retina-choroid complex. Medicine (Baltimore). 2016;95:e5729. doi:10.1097/MD.0000000000005729.
   PubMed Web of Science ®Google Scholar
• Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbands der Augenärzte Deutschlands Zur Strahlentherapie bei neovaskulärer altersabhängiger Makuladegeneration [Internet]. 2015. http://www.dog.org/wp-content/uploads/2015/10/Stellungnahme-RG-DOG-BVA-zur-Strahlentherapie-bei-neovaskulärer-altersabhängiger-Makuladegeneration.pdf
   Google Scholar
• Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, Shima DT, Ng YS. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma. Am J Pathol. 2013;182:1379–90. doi:10.1016/j.ajpath.2012.12.032.
   PubMed Web of Science ®Google Scholar
• Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27:331–71. doi:10.1016/j.preteyeres.2008.05.001.
   PubMed Web of Science ®Google Scholar
• Brar VS, Sharma RK, Murthy RK, Chalam KV. Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol Vis. 2010;16:1848–53.
   PubMed Web of Science ®Google Scholar
• Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals. 2005;14:207–21. doi:10.1159/000088637.
   PubMed Web of Science ®Google Scholar
• Sengul EA, Artunay O, Kumral ET, Yenerel M, Rasier R, Kockar A, Yuzbasioglu E. Retinal nerve fiber layer thickness changes in age-related macular degeneration treated with multiple intravitreal ranibizumab. J Ocul Pharmacol Ther. 2016;32:665–70. doi:10.1089/jop.2016.0014.
   PubMed Web of Science ®Google Scholar
• Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol. 2005;89:730–38. doi:10.1136/bjo.2004.052159.
   PubMed Web of Science ®Google Scholar
• Seregard S, Pelayes DE, Singh AD. Radiation therapy: posterior segment complications. Dev Ophthalmol. 2013;52:114–23. doi:10.1159/000351088.
   PubMedGoogle Scholar
• Durkin SR, Roos D, Higgs B, Casson RJ, Selva D. Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand. 2007;85:240–50. doi:10.1111/j.1600-0420.2006.00822.x.
   PubMedGoogle Scholar
• Girkin CA, Comey CH, Lunsford LD, Goodman ML, Kline LB. Radiation optic neuropathy after stereotactic radiosurgery. Ophthalmology. 1997;104:1634–43. doi:10.1016/S0161-6420(97)30084-0.
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Kobayashi T, Kida Y. Tolerance of the optic apparatus in single-fraction irradiation using stereotactic radiosurgery: evaluation in 100 patients with craniopharyngioma. Neurosurgery. 2010;66:688-694-695. doi:10.1227/01.NEU.0000367554.96981.26.
   PubMed Web of Science ®Google Scholar
• Lee C, Chell E, Gertner M, Hansen S, Howell RW, Hanlon J, Bolch WE. Dosimetry characterization of a multibeam radiotherapy treatment for age-related macular degeneration. Med Phys. 2008;35:5151–60. doi:10.1118/1.2990780.
   PubMed Web of Science ®Google Scholar
• Hanlon J, Firpo M, Chell E, Moshfeghi DM, Bolch WE. Stereotactic radiosurgery for AMD: a Monte Carlo-based assessment of patient-specific tissue doses. Invest Ophthalmol Vis Sci. 2011;52:2334–42. doi:10.1167/iovs.10-6421.
   PubMed Web of Science ®Google Scholar
• Cantley JL, Hanlon J, Chell E, Lee C, Smith WC, Bolch WE. Influence of eye size and beam entry angle on dose to non-targeted tissues of the eye during stereotactic x-ray radiosurgery of AMD. Phys Med Biol. 2013;58:6887–96. doi:10.1088/0031-9155/58/19/6887.
   PubMed Web of Science ®Google Scholar
• Hanlon J, Lee C, Chell E, Gertner M, Hansen S, Howell RW, Bolch WE. Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose. Med Phys. 2009;36:3671–81. doi:10.1118/1.3168554.
   PubMed Web of Science ®Google Scholar
• Raman R, Pal SS, Krishnan T, Laxmi G, Radke N, Sharma T. High-resolution optical coherence tomography correlates in ischemic radiation retinopathy. Cutan Ocul Toxicol. 2010;29:57–61. doi:10.3109/15569520903331674.
   PubMed Web of Science ®Google Scholar
• Yousef YA, Finger PT. Optical coherence tomography of radiation optic neuropathy. Ophthalmic Surg Lasers Imaging. 2012;43:6–12. doi:10.3928/15428877-20111129-09.
   PubMedGoogle Scholar
• Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Pyles EA, Yancopoulos GD, Stahl N, Wiegand SJ. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85. doi:10.1007/s10456-011-9249-6.
   PubMed Web of Science ®Google Scholar
• Hee MR, Izatt JA, Swanson EA, Huang D, Schuman JS, Lin CP, Puliafito CA, Fujimoto JG. Optical coherence tomography of the human retina. Arch Ophthalmol. 1995;113:325–32. doi:10.1001/archopht.1995.01100030081025.
   PubMedGoogle Scholar
• Sharei V, Höhn F, Köhler T, Hattenbach L-O, Mirshahi A. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;20:174–79.
   PubMed Web of Science ®Google Scholar
• Enders P, Sitnilska V, Altay L, Schaub F, Muether PS, Fauser S. Retinal nerve fiber loss in anti-VEGF therapy for age-related macular degeneration can be decreased by anterior chamber paracentesis. Ophthalmologica. 2017;237:111–18. doi:10.1159/000457907.
   PubMed Web of Science ®Google Scholar